Antoxis strengthens board with new NXD appointment

Released: Monday 27th May 2013

Antoxis is pleased to announce the appointment of Douglas Thomson as NXD to the board. Douglas has significant international experience as CEO, Business and Commercial Director of privately funded biotechnology companies having concluded over 50 deals with pharma, biotech and academic partners. Trained as an analytical chemist, previously, Douglas has worked for almost twenty years in a number of therapeutic biologics companies in executive, operational and commercial roles. He is Chairman and NXD of a number of biotech companies. 

View all News